

**To Print: Click your browser's PRINT button.**

**NOTE:** To view the article with Web enhancements, go to:  
<http://www.medscape.com/viewarticle/578502>

---

## Dysphagia Treatment Post Stroke: A Systematic Review of Randomise

Norine Foley; Robert Teasell; Katherine Salter; Elizabeth Kruger; Rosemary Martino

Age Ageing. 2008;37(3):258-264. ©2008 Oxford University Press  
Posted 08/18/2008

### Abstract and Introduction

#### Abstract

**Background:** dysphagia is common following stroke and is associated with the development of pneumonia. Many dy available, some still experimental and others already rooted in common practice. Previous reviews of these treatment available studies. Recently, more trials have been published warranting a re-examination of the evidence.

**Objective:** a systematic review of all randomised controlled trials (RCTs), updating previous work and evaluating a br interventions intended for use in adults recovering from stroke and dysphagia.

**Methods:** using multiple databases, we identified RCTs published between the years 1966 and August 2007 examini following stroke. Across studies, results of similar treatments and outcomes were compared and evaluated.

**Results:** fifteen articles were retrieved assessing a broad range of treatments that included texture-modified diets, ge non-oral (enteral) feeding, medications, and physical and olfactory stimulation. Across the studies there was heteroge the outcomes assessed that precluded the use of pooled analyses. Descriptively these findings present emerging evi not associated with a higher risk of death compared to percutaneous feeding tubes; and general dysphagia therapy p reduced risk of pneumonia in the acute stage of stroke.

**Conclusions:** dysphagia is known to be a common and potentially serious complication of stroke. Despite the recent same treatment and outcomes thereby limiting the evidence to support the medical effectiveness of common dysphae recovering from stroke.

#### Introduction

Dysphagia is prominent across the continuum of stroke recovery and its presence is likely to result in pulmonary comp Despite the perceived association between dysphagia treatment and a reduction of serious complications including as well-established evidence to support the use of any of the available treatments. In 1999, the Agency for Health Care F commissioned a large-scale, evidence-based report on the diagnosis and treatment of dysphagia in adult patients witi a lack of standardised assessment approaches and little high quality evidence for the benefit of either non-invasive sv endoscopic gastrostomy (PEG) feeding tubes. Given limitations in study design and sample size, definitive conclusio could not be drawn. At the same time a Cochrane review was conducted assessing the benefit of dysphagia treatmer identified only five trials and concluded that PEG feeding appeared to be more beneficial compared with nasogastric ( studies have been published enabling a re-examination of the evidence. Therefore, the purpose of this systematic rev evaluate a broader range of therapeutic interventions intended for use in adults recovering from stroke and dysphagia

#### Methods

##### Search Strategy and Selection Criteria

A systematic review of the literature was conducted to identify all randomised controlled trials (RCTs) evaluating therapy for dysphagia following stroke. The following databases were searched: The Cumulative Index to Nursing and Allied Health Literature (CINAHL) and the Cochrane Library. Search dates depended on the database but ranged from 1966 to August 2007. Search terms included: *deglutition disorders, dysphagia, cerebrovascular disorders/or cerebrovascular accident, randomised controlled trial, placebo or random*. The search was limited to the terms *human, adult or aged*. The reference lists of all included articles were reviewed to identify any studies not identified through the original literature search.

## Inclusions and Exclusions

This review was restricted to original parallel group RCTs published in peer-reviewed journals conducting subject-level designed trials were included, provided the order of treatments was randomly assigned. Only studies in which the subjects were recovering from stroke and who were identified as dysphagic by the study investigators were included. Studies assessing pharmacological treatments were included regardless of the length of time the intervention was provided or the outcome.

Non-English language studies and studies in which patients were not assigned randomly, by chance, to either a treatment or control group were excluded. Abstracts and Letters to the Editor were excluded because of lack of reporting detail. Opinion articles and case reports were excluded.

Two reviewers (NF and KS) independently assessed each abstract for potential inclusion. The original articles were reviewed to determine the nature of the subject's illness or the study design was not clear based on the information provided in the abstract. A single investigator (NF) abstracted data from all articles included. Two other investigators (EK, RM) confirmed for accuracy. Additionally, three authors (KS, RM and NF) independently evaluated each study using the Physiotherapy Evidence-Based Database (PEDro) scale.<sup>[4]</sup> The PEDro scale awards a maximum of 10 points for validity. Disagreement in scores among raters was resolved through consensus.

Differences between treatment groups on primary and secondary outcomes, as identified by the study's authors at the time of publication, were described and presented in table form. Similar interventions across studies were compared and common outcomes were identified.

## Results

### Literature Retrieved

The search strategy yielded 147 hits from all four databases, of which 45 were duplications, leaving 102 citations. Of these, 10 were found to be review articles, commentaries of previously published studies, or abstracts of conference proceedings and were excluded. The most common reason for exclusion was that no intervention was evaluated. Five randomised controlled trials were excluded because the participants were not dysphagic or some subjects with conditions other than stroke were included.<sup>[5-9]</sup> Fifteen RCTs were included in the review process. Of these, one study was excluded as it reported additional outcomes from a previously identified trial.<sup>[10]</sup> Fourteen studies were identified via the search strategy.<sup>[11]</sup> Therefore, a total of 15 articles met our inclusion criteria and were reviewed.<sup>[11-25]</sup>

### Methodological Quality of the Evidence

Total PEDro scores ranged from 3 to 8. Owing to the selection criteria, all studies received one point for random allocation concealment. The outcome assessor was blinded in six studies; but for pharmacological interventions, both subjects and outcome assessors were blinded. Three studies used an 'intention-to-treat' analysis. Individual studies are presented in Table 2.

### Patient Characteristics

The mean ages of patients enrolled in all studies ranged from 67<sup>[23]</sup> to 86 years.<sup>[16]</sup> The diagnosis of stroke was confirmed by a physician through a physical examination and a magnetic resonance imaging (MRI) or computed tomography (CT) scan<sup>[12,14,19-21,25]</sup> or was based on a clinical diagnosis. An eligibility criterion with respect to stroke history was explicitly stated in five trials. In three of these trials, only subjects with a first stroke were eligible to participate,<sup>[17,18,22]</sup> and subjects with stroke recurrence were eligible to participate in the remaining two trials.<sup>[12,14,17,19,20,22,23]</sup> Stroke type was reported in five trials as either ischaemic<sup>[20,22,23]</sup> or both ischaemic and haemorrhagic.<sup>[12,15]</sup> A small percentage of subjects (<1%) were found not to have experienced stroke in two trials.<sup>[12,15]</sup> Initial stroke severity was reported in all studies. On the reported information, 13 studies reported mild to moderate stroke<sup>[12,14,16]</sup> and mild stroke<sup>[20]</sup> were recruited. No details of initial stroke severity were reported in the remaining two studies.<sup>[17,18]</sup>

trials.

## Assessment of Dysphagia

In nine studies, the diagnosis of dysphagia was made on the basis of videofluoroscopic (VFS) examination,<sup>[14,17,20]</sup> or <sup>[25]</sup> or by both methods.<sup>[24]</sup> The authors of one of these trials stated that subjects diagnosed with dysphagia on the basis of VFS were excluded.<sup>[25]</sup> In four other trials, the authors stated that they enrolled patients taking a texture-modified diet, or those who had a study used swallowing difficulties identified by the patient, family member or healthcare provider to identify dysphagic patients. Latency of swallowing reflex greater than 3 s to indicate the presence of dysphagia (Ebihara, personal communication).

## Evidence Supporting Dysphagia Treatments

The 15 articles selected for review included a broad range of treatments. See Table 3 (available online at the journal's website <http://ageing.oxfordjournals.org>) for a description of interventions and outcomes. Treatment was initiated within either weeks of stroke.<sup>[14,17,20,21]</sup> The time the intervention was initiated following stroke was either highly variable<sup>[11,23]</sup> or was not stated in the remaining trials. In some of the trials, treatment was of variable duration—provisional<sup>[14,17]</sup> for the duration of their hospital stay or until the treatment was no longer required.<sup>[12,15,21,25]</sup> In the remaining trials, the duration of treatment was one to three treatments,<sup>[13,23,24]</sup> 1 week<sup>[19]</sup> or for 3 weeks to 1 month.<sup>[11,16,18,20,22]</sup> Five trials assessed outcome of treatment that varied from 6 weeks<sup>[21]</sup> to 6 months<sup>[11,12,15]</sup> to 1 year.<sup>[14]</sup> The outcomes in the remaining trials were either completion of treatment. The choice of target outcome included measurements of swallowing physiology;<sup>[16,22-24]</sup> swallowing<sup>[11,12,14,17,18,25]</sup> malnutrition;<sup>[14,20,21]</sup> and dehydration.<sup>[14,17]</sup>

In terms of study design, nine RCTs were of two-group parallel design<sup>[11,13,17-22,25]</sup> and four trials included three or more randomised crossover study<sup>[23]</sup> and two separate, but related trials, each of a two group parallel design, which were randomised. Sample sizes varied from 17<sup>[22]</sup> to 859.<sup>[15]</sup> See Table 3 (available online at the journal's website <http://ageing.oxfordjournals.org>) and results.

## Discussion

Of the 15 studies identified and reviewed, the most commonly evaluated interventions were based on dietary texture modifications,<sup>[11,17,19,25]</sup> general dysphagia therapy programmes<sup>[12,14]</sup> and enteral feeding;<sup>[15,20,21]</sup> all forms of interventions that are used in clinical practice. The outcomes assessed in these trials were usually of clinical relevance, including death, return of function, and quality of life. Other therapies evaluated in this review such as thermal<sup>[23,24]</sup> or olfactory stimulation,<sup>[16]</sup> and pharmacotherapy<sup>[22]</sup> aim to improve aspects of swallowing, are currently considered to be experimental and are not yet in routine use. Finally, two interventions that target the digestive tract<sup>[18]</sup> and subcutaneous hydration,<sup>[13]</sup> have been used, historically, in conditions other than stroke. The interventions were provided during the first several weeks following stroke, although some were provided in the chronic stage when patients are discharged.<sup>[11,16]</sup> Although the review was restricted to RCTs, the methodological quality of the trials was generally only fair. Only a few trials met design elements most often associated with decreased risk of bias. (concealment of the randomisation schedule, blinding, and intention-to-treat analysis). The heterogeneity of the interventions, even within the same broad treatment categories, and the range of outcomes assessed made pooled analyses inappropriate; therefore, the results were presented descriptively. For two swallowing treatment programmes there were a sufficient number of trials available to enable comment on the strength of evidence.

Three RCTs compared the outcomes of acute stroke patients who were fed using NG or PEG feeding tubes.<sup>[15,20,21]</sup> One was a large, multicentre trial.<sup>[15]</sup> In this trial patients randomised to the NG group were less likely to experience either death or pneumonia compared to patients fed with a PEG tube ( $P = 0.05$ ), and were no more likely to develop pneumonia. However, these two other smaller RCTs reviewed,<sup>[20,21]</sup> where NG tubes were associated with a higher risk of death and worse outcomes, including more feeding interruptions due to mechanical failures, blockages and dislodgements when compared with PEG tubes. These findings give greater consideration to the FOOD trial with its larger sample size and higher methodological quality score, suggesting that tube feeding is not associated with a greater risk of death compared with PEG feeding. However, PEG tube feeding is associated with tube failures and fewer declines in nutritional status.

Two RCTs were identified that assessed the effectiveness of general swallowing treatment programmes.<sup>[12,14]</sup> Typical of these trials and executed by speech-language pathologists. They comprise of a variety of compensatory and treatment-swallowing programmes. Texture-modified diets that have been shown during a VFS assessment to be effective in reducing aspiration or improving swallowing. There were similarities between the two studies inasmuch as both included three groups providing treatment at varying intensities. The trials<sup>[14]</sup> did not include a true control condition, to enable treatment comparisons, we presumed the group receiving no treatment as the control group. Unfortunately, the authors of this study did not report the actual treatment intensity patients received.

differed from that described since patients were permitted additional instruction upon request. The studies provided to one acutely, within 7 days<sup>[12]</sup> and the other, at 4 1/2 weeks<sup>[14]</sup> post stroke with differing degrees of intensity. One of the arms that provided swallowing exercises in addition to compensatory swallowing techniques. Two outcomes, death and pneumonia, were assessed in both studies. No deaths were reported in the trial assessing subjects in the rehabilitative phase of stroke; however, there were conflicting results in terms of reductions in pneumonia. Even though the sample sizes were small and statistical significance<sup>[14]</sup> reported that patients receiving the lowest intensity of therapy had the lowest incidence of pneumonia. In contrast, patients receiving the lowest intensity of treatment (usual care) had a significantly higher incidence of chest infection than those receiving more intensive therapies. In summary, the overall evidence suggests that swallowing treatment programmes are associated with a lower incidence of pneumonia in at least the acute stage of stroke; however, a larger, adequately powered study is required to establish the benefit of swallowing treatment in the rehabilitation phase of stroke.

The benefit of dietary texture modifications and/or alteration of fluid viscosity was evaluated in four trials.<sup>[11,17,19,25]</sup> Although we reviewed and evaluated a common outcome (pneumonia), we were still unable to summarise the overall benefit of treatment due to heterogeneity of interventions, timing and duration of therapy and stage of recovery of study participants. The sample sizes were small, ranging from 20<sup>[17]</sup> to 56<sup>[11]</sup> and the event rates for pneumonia were low in two of the three studies.<sup>[17,25]</sup> The external validity of at least one of the studies is limited because the inclusion criteria were highly restrictive such that almost five times the number of available patients were excluded. The simultaneous manipulation of solid textures and fluid viscosities makes it difficult to establish which component (solid or liquid) provides the greatest pulmonary benefit. In summary, although modifications in dietary textures and fluid viscosities are a common dysphagia treatment, the current evidence of its medical effectiveness is limited.

Four RCTs were designed to improve the physiological aspects of swallowing by means of three different interventions: channel blocker,<sup>[22]</sup> olfactory stimulation (aromatherapy) with black pepper oil<sup>[16]</sup> and the use of a cold stimulus on the tongue. The plausible mechanism through which treatment could be predicted to improve physiological aspects of the swallow was the evidence from these trials is weakened by small sample sizes, the lack of a no treatment control group,<sup>[24]</sup> the reporting of statistical comparisons,<sup>[22]</sup> the use of more than one treatment<sup>[24]</sup> or control group<sup>[16]</sup> and the failure to identify<sup>[22,23]</sup> or achieve<sup>[24]</sup> a clinically significant treatment effect. In summary, the current evidence is insufficient to recommend the clinical application of any of these three treatments.

Hypodermoclysis or subcutaneous hydration has been evaluated primarily in the elderly and palliative populations where intravenous hydration is impossible to achieve.<sup>[26]</sup> The single RCT<sup>[13]</sup> we reviewed evaluating this technique specifically within the stroke population was not effective compared with the intravenous route for maintaining serum osmolality within a normal range for three consecutive days. Subcutaneous hydration remains uncommon practice likely due to its disadvantages that include the risk of tissue damage and the need for the treatment to be safely administered.<sup>[26]</sup> Although the use of hypodermoclysis is not a treatment for dysphagia *per se*, the single trial was included in this review because of its inclusion criteria and was included.

The use of anti-microbial agents as a means to reduce the colonisation of pathogenic organisms in portions of the digestive tract in stroke patients is a topic that has been investigated in other patient groups other than stroke. The use of selective decontamination of the digestive tract (SDD) has been investigated in intensive care setting requiring artificial ventilation, where it has been shown to reduce the incidence of nosocomial infection. A modified version of this intervention, whereby SDD was applied only as a topical gel rather than one component of a regimen, was evaluated specifically for use in patients recovering from stroke in a single trial.<sup>[18]</sup> SDD was associated with a lower incidence of pneumonia, particularly for patients with an abnormal swallow; however, there was no difference in mortality between the two groups. Although it remains to be established if the treatment is cost-effective, a larger and more rigorous study is required to evaluate the use of SDD in patients recovering from stroke.

This systematic review sought to review all published RCTs evaluating therapeutic swallowing interventions for dysphagia. The quality and scope of the empirical evidence. Although the literature search was extensive and we believe all potential relevant studies were identified, it is possible that some were missed. Since this review was restricted to RCTs, the most rigorous study design, we did not include non-RCTs. Additionally, the contribution to the literature of non-RCTs was not considered in this review. Some forms of experimental dysphagia treatment, such as lingual strengthening exercises, biofeedback, electrical stimulation and others were not evaluated in this review since they have not yet been subjected to a rigorous evaluation.

## Conclusions

This updated review of all treatments for dysphagia, a common and potentially serious complication of stroke, identified a number of treatments including texture-modified diets, swallowing therapy programmes, non-oral feeding, medications and pH modification. However, due to the small number of trials as well as heterogeneity of treatments evaluated and outcomes assessed, the current evidence does not have definitive implications for clinical practice, with two exceptions. First, NG tubes do not appear to be associated with a higher incidence of pneumonia compared with PEG feeding tubes. Second, general swallowing treatment programmes are associated with a reduced incidence of pneumonia.

of stroke. Until further evidence emerges, we will be forced to rely on clinical experience and consensus opinions as t Although evidence of effectiveness is lacking for many swallowing therapies and interventions now in current practice discontinued, since current treatments have their roots in clinical experience and approaches that are physiologically clear and pressing need for high-quality research to identify effective dysphagia treatments post stroke.

**Table 1. Literature Search Outcome**

	Medline	Embase	CCTR	Cinahl	Total
Hits on database	52	37	48	10	147
Exclusions:					
Duplication between database	—	14	26	5	45
Review articles	4	4	0	1	9
Non-English language	2	2	1	—	5
No intervention evaluated	18	5	2	1	26
No control group	2	—	—	—	2
Non-random assignment	5	—	1	—	6
Some/all subjects had not suffered a stroke	1	4	3	—	8
Some/all subjects not dysphagic	1	5	1	—	7
Commentary or letter to editor	9	—	1	2	12
Abstract of conference proceeding	—	—	12	—	12
RCTs remaining	10	3	1	1	15

**Table 2. PEDro Criteria and Final Scores of 15 Included Trials**

Article	Random assignment	Concealed allocation	Baseline comparisons	Between group comparison	Blinding			Adequa follow-t
					Patient	Clinician	Assessor	
Carnaby <i>et al.</i> 2006 [12]	X	X	X	X	—	—	X	X
Challiner <i>et al.</i> 1994 [13]	X	X	X	X	—	—	—	X
DePippo <i>et al.</i> 1994 [14]	X	—	X	X	—	—	—	X
Ebihara <i>et al.</i>	X	—	X	X	—	—	—	X

2006 [16]								
The FOOD trial, 2005 [15]	X	X	X	X	—	—	—	X
Garon <i>et al.</i> 1997 [17]	X	—	X	X	—	—	—	X
Gosney <i>et al.</i> 2006 [18]	X	X	X	X	X		X	X
Goulding and Bakheit 2000 [19]	X	—	X	X	—	—	X	X
Groher 1987 [11]	X	—		X	—	—	—	X
Hamidon <i>et al.</i> 2006 [20]	X	—	X	X	—	—	—	X
Norton <i>et al.</i> 1996 [21]	X	X	X	X				X
Perez <i>et al.</i> 1998 [22]	X		X	—	X		X	X
Rosenbek <i>et al.</i> 1996 [23]	X	—	—	X	—	—	X	X
Rosenbek <i>et al.</i> 1998 [24]	X	X		X			X	X
Whelan 2001 [25]	X		—	X	—	—	—	X

## References

1. Martino R, Foley N, Bhogal S, et al. Dysphagia after stroke: incidence, diagnosis, and pulmonary complication
2. Diagnosis and Treatment of Swallowing Disorders (Dysphagia) in Acute-care Stroke Patients. (1999) (Evidence 8) Rockville, MD: AHCPR Publication No.99-E024, Agency for Health Care Policy and Research.
3. Bath PM, Bath FJ, Smithard DG. Interventions for dysphagia in acute stroke. *Cochrane Database Syst Rev* (1 Doi:10.1002/14651858. CD000323.
4. Moseley AM, Herbert RD, Sherrington C, et al. Evidence for physiotherapy practice: a survey of the Physiothe Aust J Physiother (2002) 48:43-9.
5. Potter J, Robinson T, Ford G, et al. CHHIPS (Controlling Hypertension and Hypotension Immediately Post Str Hypertens (2005) 23:649-55.
6. Pittock SJ, Moore AP, Hardiman O, et al. A double-blind randomised placebo-controlled evaluation of three dc (Dysport) in the treatment of spastic equinovarus deformity after stroke. *Cerebrovasc Dis* (2003) 15:289-300.
7. Weber RS, Berkey BA, Forastiere A, et al. Outcome of salvage total laryngectomy following organ preservatio

- Oncology Group trial 91-11. *Arch Otolaryngol Head Neck Surg* (2003) 129:44-9.
8. Carlsson CM, Papcke-Benson K, Carnes M, et al. Health-related quality of life and long-term therapy with pravastatin in older adults. *Drugs Aging* (2002) 19:793-805.
  9. Sacco RL, DeRosa JT, Haley EC Jr, et al. Glycine antagonist in neuroprotection for patients with acute stroke: a controlled trial. *JAMA* (2001) 285:1719-28.
  10. Dennis M, Lewis S, Cranswick G, et al. FOOD: a multicentre randomised trial evaluating feeding policies in patients with a recent stroke. *Health Technol Assess* (2006) 10:iii-iv, ix-x.
  11. Groher ME. Bolus management and aspiration pneumonia in patients with pseudobulbar dysphagia. *Dysphagia* (1998) 13:195-7.
  12. Carnaby G, Hankey GJ, Pizzi J. Behavioural intervention for dysphagia in acute stroke: a randomised controlled trial. *Stroke* (2005) 36:1005-10.
  13. Challiner YC, Jarrett D, Hayward MJ, et al. A comparison of intravenous and subcutaneous hydration in elderly patients. *J* (1994) 70:195-7.
  14. DePippo KL, Holas MA, Reding MJ, et al. Dysphagia therapy following stroke: a controlled trial [see comment]. *Stroke* (2005) 36:1005-10.
  15. Dennis MS, Lewis SC, Warlow C. Effect of timing and method of enteral tube feeding for dysphagic stroke patients: a randomised controlled trial. *Lancet* (2005) 365:764-72.
  16. Ebihara T, Ebihara S, Maruyama M, et al. A randomized trial of olfactory stimulation using black pepper oil in patients with olfactory dysfunction. *J Am Geriatr Soc* (2006) 54:1401-6.
  17. Garon BR, Engle M, Ormiston C. A randomized control trial to determine the effects of unlimited oral intake of food in patients with aspiration. *J Neurol Rehabil* (1997) 11:139-48.
  18. Gosney M, Martin MV, Wright AE. The role of selective decontamination of the digestive tract in acute stroke. *Stroke* (1998) 29:1005-10.
  19. Goulding R, Bakheit AM. Evaluation of the benefits of monitoring fluid thickness in the dietary management of patients with dysphagia. *Rehabil* (2000) 14:119-24.
  20. Hamidon BB, Abdullah SA, Zawawi MF, et al. A prospective comparison of percutaneous endoscopic gastrostomy and nasogastric tube feeding in patients with acute dysphagic stroke. *Med J Malaysia* (2006) 61:59-66.
  21. Norton B, Homer-Ward M, Donnelly MT, et al. A randomised prospective comparison of percutaneous endoscopic gastrostomy and nasogastric tube feeding after acute dysphagic stroke. *BMJ* (1996) 312:13-6.
  22. Perez I, Smithard DG, Davies H, et al. Pharmacological treatment of dysphagia in stroke. *Dysphagia* (1998) 13:195-7.
  23. Rosenbek JC, Roecker EB, Wood JL, et al. Thermal application reduces the duration of stage transition in dysphagia. *Stroke* (1998) 29:1005-10.
  24. Rosenbek JC, Robbins J, Willford WO, et al. Comparing treatment intensities of tactile-thermal application. *Dysphagia* (1998) 13:195-7.
  25. Whelan K. Inadequate fluid intakes in dysphagic acute stroke. *Clin Nutr* (2001) 20:423-8.
  26. Barton A, Fuller R, Dudley N. Using subcutaneous fluids to rehydrate older people: current practices and future research. *Age Ageing* (2006) 35:100-4.
  27. D'Amico R, Pifferi S, Leonetti C, et al. Effectiveness of antibiotic prophylaxis in critically ill adult patients: a systematic review of randomised controlled trials. *BMJ* (1998) 316:1275-85.

## Sidebar: Key Points

- Fifteen RCTs have evaluated the benefit of general dysphagia therapy programmes, non-oral feeding, medication, and sensory stimulation in the treatment of post stroke dysphagia.
- The risk of death associated with the use of nasogastric and percutaneous endoscopic gastrostomy (PEG) tubes declines in variables associated with nutritional status are associated with the use of PEG tubes.
- There is emerging evidence that general dysphagia programmes reduce the risk of pneumonia in the acute stroke population.
- Despite the recent addition of several newly published RCTs, few utilise the same treatment and outcomes; this research continues to be limited.

## Funding Information

This research was supported by funds received from the Canadian Stroke Network. The financial sponsors played no role in the interpretation of data or writing of the study.

## Reprint Address

Norine Foley. Tel: 1 (519) 685-4292 ext 42738; Fax: (519) 685-4036. E-Mail: [norine.foley@sjhc.london.on.ca](mailto:norine.foley@sjhc.london.on.ca)

**Norine Foley,<sup>1</sup> Robert Teasell,<sup>2</sup> Katherine Salter,<sup>1</sup> Elizabeth Kruger,<sup>1</sup> and Rosemary Martino<sup>3</sup>**

<sup>1</sup>Research Associate, Aging, Rehabilitation and Geriatric Care Program, Lawson Health Research Institute, Parkwood  
Commissioner's Rd. E. London, ON N6C 5J1, Canada

<sup>2</sup>Department of Physical Medicine and Rehabilitation, Parkwood Hospital, 801 Commissioner's Rd. E. London, ON N6

<sup>3</sup>Graduate Department of Speech-Language Pathology, Rehabilitation Sciences Building, Centre for Function and We  
University of Toronto, 500 University Ave, 10th floor, Toronto, ON M5G 1V7, Canada

Disclosure: Rosemary Martino is supported by a Canadian Institutes of Health Research New Investigator Award in A

Conflicts of Interest: None

---